The facts and information provided to users in the pages of RepliCel Life Science Inc.’s website are for informational purposes only. Users should not rely on information on this website for any purpose other than for gaining general knowledge of RepliCel Life Sciences. This information is not intended to be and should not be construed in any way as part of an offering or solicitation of securities in any jurisdiction. No securities commission or other regulatory authority in Canada, the United States or any other country or jurisdiction has in any way passed upon the information contained in this website.
The information on this website contains forward-looking statements, as that term is defined under applicable securities laws. Statements in this website, which are not purely historical, are forward-looking statements and can include, without limitation, statements based on current expectations involving a number of risks and uncertainties and which are not guarantees of future performance of the Company such as the statements that: (1) the ReplicelTM hair cell replication technology has the potential to become the world’s first non-surgical permanent cure for androgenetic alopecia and general hair loss in both men and women; (2) the Company’s scientists anticipate the dermal sheath cup cells will develop hair-producing follicles and initiate natural hair regeneration; (3) the dermal sheath cup cells will migrate into follicles that are still present but in early stages of damage as a rejuvenation measure and also a preventative measure against further miniaturization of the hair follicle; (4) the new hair follicles and rejuvenated hair follicles will have resistance to miniaturization caused by androgen hormones; (5) human scalp areas treated using RepliCel’s process will show increased hair count and density; (6) the Company willl develop a safe, evidence-based, non-surgical procedure to treat various types of hair loss in men and women; (7) the Company will discover a potential successful treatment for hair loss in humans; (8) the ReplicelTM chronic Achilles tendinosis technology has the potential to permanently restore a tendons strength and function; (9) the Company’s scientists anticipate the non-bulbar dermal sheath fibroblast cells will create new type 1 collagen, that the non-bulbar dermal sheath fibroblast cells will jump-start/initiate the healing process; (10) that the non-bulbar dermal sheath fibroblast cells will migrate into damaged areas of the tendon; (11) that the RepliCelTM skin rejuvenation technology as the potential to reverse the signs of UV-damage and aging; (12) that the non-bulbar dermal sheath fibroblast cells will re-build type-1 collagen and elastin in the skin; (13) that the non-bulbar dermal sheath fibroblast cells will adapt to the microenvironment and respond to the mechanical or surrounding stimuli after injection; (14) that the non-bulbar dermal sheath fibroblast cells will properly align within the tissue; (15) that the non-bulbar dermal sheath fibroblast cells will migrate into the dermis of the skin; (16) that the company will obtain a CE mark for its dermal injector device; (17) that the dermal injector device will be licensed for other dermal applications.
These statements are only predictions and involve known and unknown risks, including the risks in the section entitled “Risk Factors” in the Company’s Form 20-F filed for the fiscal year ended December 31, 2010, uncertainties and other factors, which may cause the Company’s or its industry’s actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. These risks and uncertainties include:
- negative results from the Company’s clinical trials, including that the Company’s hair cell replication technology, tendon repair technology and skin rejuvenation technology may not work as planned or may not be an effective treatment;
- the effects of government regulation on the Company’s business;
- the viability and marketability of the Company’s hair rejuvenation, tendon repair, dermal injector and skin rejuvenation technologies;
- the Company’s failure to successfully implement its marketing plan;
- the development of superior technology by the Company’s competitors;
- the failure of consumers and the medical community to accept the Company’s technology as safe and effective;
- risks associated with the Company’s ability to obtain and protect rights to our intellectual property;
- risks and uncertainties associated with the Company’s ability to raise additional capital; and
- other factors beyond the Company’s control.
Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement.
Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company’s annual report on Form 20-F for the fiscal year ended December 31 and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at www.sec.gov and with the Canadian Securities Commissions on Sedar at www.sedar.com.
Although RepliCel Life Sciences believes the facts and information contained in the pages of this website to be correct and attempts to keep this information as current as possible, the Company does not warrant or make any representations as to the accuracy, validity or completeness of any facts or information contained in this website.
RepliCel Life Sciences shall not be liable or responsible for any claim or damage, direct or indirect, special or consequential, incurred by the user arising out of the interpretation, reliance upon or other use of the information contained in this website.
Any hyperlinks to or from this website from or to another website is provided to the user for convenience only. No endorsement of any products or services is expressed or implied by any information, material or content referred to or included on, or linked from this website.
Trademarks and Copyright
RepliCel and other graphics, logos, page headers, button icons, scripts, and service names of the Company are trademarks, registered trademarks or trade dress of the Company in Canada, the United States and/or other countries. The Company’s trademarks and trade dress may not be used in connection with any product or service that is not the Company’s product or service, in any manner that is likely to cause confusion among customers, or in any manner that disparages or discredits the Company. All other trademarks not owned by the Company that appear on this website are the property of their respective owners, who may or may not be affiliated with, connected to, or sponsored by the Company.
The products and services described in the pages of the RepliCel Life Sciences’s website are only offered in jurisdictions where they may be legally offered for sale.
Confidentiality and security of information provided over the Internet is not possible at this time. RepliCel Life Sciences cannot ensure the privacy and authenticity of any information or correspondence shared over the Internet between it and a user, and will not be responsible for any damages or claims incurred by a user who communicates confidential information to RepliCel Life Sciences through this website.